The effect of GM-CSF on the differentiation of monocytes has been also addressed and found comparable in control and LPI cells, providing a rationale for GM-CSF therapy in LPI-associated PAP. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.